RXi Publications and Publications of RXi Licensed Technology
Wang H, Ghosh A, Baigude H, Yang C, Qui L, Xia L, Zhou H, Rana TM, & Xu Z (2008) Therapeutic gene silencing delivered by a chemically modified siRNA against mutant SOD1 slows ALS progression. JBC, Mar 2008
Salomon W, Pavco P, Kamens J Mechanisms of action for RNAi with chemically modified duplexes. Poster, March 2008, Keystone Symposium on RNAi
Fire A, Xu S, Montgomery MK, Kostas SA, Driveri SE & Mello C (1998) Potent and specific RNA interference by double-stranded RNA in Caenorhadbditis elegans. Nature, Vol. 391, Feb 1998
Baigude H, McCarroll J, Yang C, Swain PM, & Rana TM (2007) Design and creation of new nanomaterials for therapeutic RNAi. ACS Chemical Biology, Vol.2 No.4
Chiu Y and Rana TM (2002) RNAi in human cells: Basic structural and functional features of small interfering RNA. Molecular Cell, Vol. 10, 549–561, Sept 2002
Leonardsson G, Steel JH, Christian M, Pocock V, Milligan S, Bell J, So P, Medina-Gomez G, Vidal-Puig A, White R, & Parker MG (2004) Nuclear receptor corepressor RIP140 regulates fat accumulation. Proceedings of the National Academy of Science USA 101, 8437-8442.
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K & Tuschl T (2001) Duplexes of 1±nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, Vol. 411, May 2001.
Richard I. Hogrefe, Alexandre V. Lebedev, and Gerald Zon Kathleen F. Pirollo, Antonina Rait, Qi Zhou, Wei Yu, and Esther H. Chang. Chemically modified short interfering hybrids (siHYBRIDS): Nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides, Nucleotides, and Nucleic Acids, 25:889–907, 2006
Powelka AM, Seth A, Virbasius JV, Kiskinis E, Nicoloro SM, Guilherme A, Tang X, Straubhaar J, Cherniack AD, Parker MG, and Czech MP (2006) Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes. The Journal of Clinical Investigation, Volume 116, Number 1, January 2006
Other Prior Publications of RXi Staff and Advisors
Grishok A, Shin T-H, Tabara H, & Mello CC (2000) Genetic requirements for the inheritance of RNAi in C. elegans. Science, 287, 2494-2497
Parish S, Fleenor J, Xu S, Mello C, & Fire A (2000) Functional anatomy of a dsRNA trigger: Differential requirements for the two trigger strands in RNA interference. Molecular Cell, 6, 1077-1087
Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Baillie DL, Fire A, Ruvkun G, & Mello CC (2001) Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control developmental timing in Caenorhabditis elegans. Cell, 106, 23-34
Tabara H, Yigit E, Siomi H, & Mello CC (2002) The dsRNA binding protein RDE-4 interacts with RDE-1, DCR-1, and a DExH-Box helicase to direct RNAi in C. elegans. Cell, 109, 1-20
Hough SR, Wiederholt KA, Burrier AC, Woolf TM, & Taylor MF (2003) Why RNAi makes sense. Nature Biotechnology, 20:4
Woolf TM (1998) Therapeutic repair of mutated RNA sequences. Nature Biotechnology, March 1998
Woolf TM (1996) It's not the size, it's the potency. Nature Biotechnology, Invited Commentary, August 1996
Woolf TM, Chase JM, Stinchcomb D (1995) Toward the therapeutic editing of mutated RNA sequences. Proceedings of the National Academy of Science, 92(18):8298-302
Woolf T, Melton D, and Jennings C (1992) Specificity of antisense oligonucleotides in vivo. Proceedings of the National Academy of Science, 89:7305-7309
Girard A, Sachidanandam R, Hannon GJ, & Carmell MA (2006) A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature, 442:199–202
He L, Thomson JM, Hemann MT, Mu D, Powers S, Hernando-Monge E, Goodson S, Cordon-Cardo C, Lowe SW, Hannon GJ, & Hammond SM (2005) A microRNA polycistron as a potential human oncogene. Nature, 435:828–833
Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song J-J, Hammond SM, Joshua-Tor L, & Hannon GJ (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science, 305:1437–1441
Paddison PJ, Silva JM, Conklin DS, Schlabach M, Li M, Aruleba S, Balija V, O’Shaughnessy A, Gnoj L, Scobie K, Chang K, Westbrook T, Cleary M, Sachidanandam R, McCombie WR, Elledge SJ, & Hannon GJ (2004) A resource for large-scale RNAi based screens in mammals. Nature, 428:427–431
Bose A, Guilherme A, Robida SI, Nicoloro SMC, Zhou QL, Jiang ZY, Pomerleau DP & Czech MP (2002) Glucose transporter recycling in response to insulin is facilitated by myosin. Nature, 420:19-26, Dec 2002
Taylor JT, Zhang QQ, Wyatt JR, & Dean NM (1999) Induction of endogenous BCL-xS through the control of BCL-x pre-mRNA splicing by antisense oligonucleotides. Nature Biotechnology, 17:1097-1100
Jenne A, Hartig J, Piganeau N, Tauer A, Samarsky DA, Green MR, Davies J & Famulok M (2001) Rapid identification and characterization of hammerhead-ribozyme inhibitors using fluorescence-based technology. Nature Biotechnology, 19:56-61
Pavco PA, Bouhana KS, Gallegos AM, Agrawal A, Blanchard KS, Grimm SL, Jensen KL, Andrews LE, Wincott FE, Pitot PA, Tressler RJ, Cushman C, Reynolds MA, & Parry TJ (2000) Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors, Clinical Cancer Research, 2094 6:2094–2103, May 2000
Lee PA, Blatt LM, Blanchard KS, Bouhana KS, Pavco PA, Bellon L, & Sandberg JA (2000) Pharmacokinetics and tissue distribution of a ribozyme directed against Hepatitis C virus RNA following subcutaneous or intravenous administration in mice. Hepatology, 32(3)
Samarsky DA, Ferbeyre G, Bertrand E, Singer RH, Cedergren R, & Fournier MJ (1999) A small nucleolar RNA:Ribozyme hybrid cleaves a nucleolar RNA target in vivo with near-perfect efficiency. Proceedings of the National Academy of Science, 96:
